Host: |
HEK293 cells |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Formulation: |
Lyophilised from a 0.22 Mu m filtered solution of PBS, pH 7.4. |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Determination Method: |
< 0.1 EU/Mu g of the protein by LAL method. |
Immunoreactivity: |
1.Measured by its binding ability in a functional ELISA. Immobilized Human BMP2 at 4 Mu g/mL (100 Mu L/well) can bind Human BMPRIB with a linear range of 20-338 ng/mL.|2.Measured by its ability to inhibit rhBMP-4-induced alkaline phosphatase producti |
Gene Symbol: |
BMPR1B |
Gene ID: |
658 |
Uniprot ID: |
BMR1B_HUMAN |
Immunogen: |
Active Recombinant Human BMPR-1B/ALK-6 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Lys14-Arg126) of human BMPR-IB/ALK-6 (Accession #NP_001194.1) fused with a Fc, 6×His tag at the C-terminus. |
Immunogen Sequence: |
KKEDGESTAPTPRPKVLRCK CHHHCPEDSVNNICSTDGYC FTMIEEDDSGLPVVTSGCLG LEGSDFQCRDTPIPHQRRSI ECCTERNECNKDLHPTLPPL KNRDFVDGPIHHR |
Function | On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for BMP7/OP-1 and GDF5. Positively regulates chondrocyte differentiation through GDF5 interaction. |
Protein Name | Bone Morphogenetic Protein Receptor Type-1bBmp Type-1b ReceptorBmpr-1bCd Antigen Cdw293 |
Database Links | Reactome: R-HSA-201451 |
Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane Protein |
Alternative Protein Names | Bone Morphogenetic Protein Receptor Type-1b proteinBmp Type-1b Receptor proteinBmpr-1b proteinCd Antigen Cdw293 proteinBMPR1B protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance